These results, coupled with the observation that specifically deleting Xbp1 in hepatic macrophages can prevent MASH induced by FFC diet feeding, provide strong experimental evidence for FT@XBP1 as an attractive treatment strategy for MASH progression. This evidence concerns the gene XBP1 and metabolic dysfunction-associated steatohepatitis.